Introduction
Pimozide is the first of a new series of psychotropic drugs, the diphenylbutylpiperidines. It is a recently introduced neuroleptic of proven antipsychotic efficacy (Henrich & Quaschning 1971 , Sugerman 1971 . In controlled trials, pimozide has been compared with most standard neuroleptics as maintenance therapy in chronic schizophrenia. These studies have been reviewed by Pinder et al. (1976) . Overall, no significant difference between pimozide and the other neuroleptics has been found, although there is a tendency to regard pimozide as more beneficial in patients with social withdrawal (Kolivakis et al. 1974) , decreased social competence , unusual thought content, hallucinations and delusions.
These workers have stressed the improvement in social attitudes and relationships in patients given the drug. Kristjansen (1971) and Janssen et al. (1972) have suggested that the drug is a useful adjunct to social rehabilitation. Much of this benefit may be associated with the lack of sedative properties and low incidence of adverse effects claimed for it. It is generally felt that pimozide is not appropriate therapy for depressed, excited, anxious, aggressive or hyperactive patients.
The dose range has varied between studies. In an early tolerance investigation by Clark et al. (1971) , 20 mg/day was not well tolerated by normal volunteers, who complained of nervousness, restlessness, insomnia, drowsiness, listlessness and fatigue. However, 9 schizophrenic patients received up to 40 mg/day with only mild unwanted effects. Sugerman (1971) prescribed doses of 12-30 mg daily in 5 patients, all of whom tolerated the therapy and either maintained their condition as well as on previous medication, or improved. In a double blind comparison with chlorpromazine (Kolivakis et al. 1974 ), using individually titrated doses, no significant difference was found between pimozide (in a dose range of 2.5-21 mg daily) and chlorpromazine (75-450 mg daily).
In another comparative study, pimozide, given in a dose range of 3-9 mg daily was superior to trifluoperazine in doses from 3-12 mg daily as Dr T R E Barnes maintenance therapy in chronic schizophrenic patients (Andersen et al. 1974) . A recent study by Donlon et at. (1977) compared pimozide (2-20 mg/day) and fluphenazine (3-30 mg/day) using flexible dosage regimes. Chronic schizophrenic patients received an average daily pimozide dose of 9.6 mg over 35 weeks and this proved equal to fluphenazine as effective maintenance therapy. A study involving acutely ill schizophrenic patients used doses of up to 60 mg/day and reported that pimozide was both clinically effective and well tolerated (Shopsin & Selzer 1977) . Pinder et al. (1976) , in a detailed review article, suggest an initial dose of 2-4 mg/day in chronic schizophrenia. This dose may then be increased until the maintenance level is reached, in most cases about 6 mg/day. They recommend a maximum daily dose of 10 mg and conclude that no advantage seems to be gained from increasing the dosage to over 20 mg/day.
This study was designed to determine whether there is a population of chronic schizophrenic patients who, while not deriving any benenft from the normal 2-10 mg dose range, might show a therapeutic response to a higher dosage. Should such a group exist, we hoped to discover whether pimozide therapy had any advantages over their previous maintenance neuroleptic medication.
MATERIALS AND METHODS

Patients
Fourteen inpatients with chronic schizophrenia, all with a previous history of florid symptoms, were involved in the study. They comprised 11 males and 3 females, ranging in age from 32-76 years (mean, 48.6) and were selected principally on the basis of 'negative' symptoms such as emotional flatness, social withdrawal, poverty of speech and apathy. Patients had to be in good physical health and were excluded if there was a history of alcoholism, drug dependence or epilepsy. Women who were pregnant were not included. Patients with a history of clear-cut depressive episodes or suicidal tendencies, recent displays of aggression, marked agitation and excitement or psychomotor hyperactivity, were not considered suitable for the study.
All patients had received maintenance therapy with a standard neuroleptic for at least 6 months prior to the beginning of the trial, during which time their illness had remained stable. Nine patients had been receiving oral neuroleptic medication. The -dosages have been converted to chlorpromazine equivalents (Davis 1974) , giving a dose range of 100-1464 mg/day (mean daily dose, 436 mg). Five patients had received depot neuroleptic medication (fluphenazine decanoate in all cases). The dose range was 25 mg every four weeks to 75 mg every two weeks. Hamilton et al. (1960) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE) of Honigfeld & Klett (1965) were carried out. Extrapyramidal side-effects were assessed using the rating scale devised by Simpson & Angus (1970) . All ratings were administered at fortnightly intervals, except for the period of dosage manipulation, during which they were carried out weekly. Adverse effects were noted at the same time, the most common known side-effects being elicited by direct enquiry.
Following 'base line' assessment and full hmmatological and biochemical investigation, the patients' neuroleptic and anticholinergic drugs were abruptly discontinued and pimozide 4 mg/ day was substituted. Patients remained on this dosage unchanged for 6 weeks. It was hoped that, in this way, any changes, therapeutic or otherwise, consequent upon withdrawal of the maintenance neuroleptic would not be falsely attributed to pimozide therapy. After 6 weeks, the dose was increased each week by 4 mg/day until a favourable response had been achieved and further increase produced no further improvement or deterioration. The maximum daily dose allowed was 24 mg. The individual optimum dose was thus determined and patients were continued on this for a further 4 weeks.
Full hiematological and biochemical monitoring was carried out at fortnightly intervals, while pulse rate and blood pressure, both standing and lying, were recorded daily.
RESULTS
Investigations
Haematological and biochemical investigations did not reveal any abnormalities during the study. There were very slight falls in the mean systolic and diastolic blood pressures when the recordings in the first and last weeks of the study were compared but these were not significant. Body weight showed a mean increase of +0.43 kg (range, -4.0 to +5.5 kg).
Adverse Eeftcts
Throughout the trial there was no subjective or objective evidence of recognized side-effects such as drowsiness, headache, anorexia, nausea, abdominal pain, restlessness or insomnia.
Prior to the beginning of the trial, 5 patients had been receiving anticholinergic medication. This was omitted on entry to the study and readministration was indicated in only 1 of these cases. Two other patients, not previously on anticholinergic medication, required these drugs when receiving relatively high doses of pimozide. For all other patients, the degree of drug-induced motor disturbance remained essentially unchanged for the duration of the study. 
Withdrawals
Four patients were withdrawn from the study following the abrupt onset of aggression and violence directed towards other patients and staff. Two were receiving pimozide 20 mg/day, 1 was receiving 16 mg/day and the other 8 mg/day. In all cases, this behaviour was clearly associated with paranoid delusional ideas. Three of these patients had been given relatively high irritability scores at first assessment, compared with the rest of the sample.
PSE
This proved to be an unsuitable scale for rating this particular patient population. It was only possible to score sections 18-20 (behaviour, affect and speech) in most cases.
PRS
The mean scores on 4 occasions during the study are presented in Fig 2. Using a t test of differences for correlated means to compare the base line and final scores, the improvement was found to be significant (t= 2.94, df=9, P<0.05).
NOSIE
This 32-item scale generates 7 sub-scores, 4 'asset' factors (social competence, social interest, cooperation and personal neatness) and three 'liability' factors (irritability, psychotic depression and manifest psychosis). The results are presented in Fig 2. Using the same statistical analysis as described above, the reduction in the mean score for irritability was significant (t=3.63, P<0.01), as was the increase in the mean score for social interest (t= 2.34, P<0.05).
CONCLUSIONS
The maximum daily dose of pimozide in chronic schizophrenia has been generally considered to be 10 mg/day. From our results it seems that it may well be of value, in selected patients, to titrate dose against individual response to a maximum of 20 mg/day. In this study, pimozide was found to increase social interest and social competence and to reduce irritability and residual psychotic features. The improvements in social interest and irritability were statistically significant.
High doses of pimozide should be prescribed with caution because of the danger of abrupt onset of aggressive, psychotic behaviour. Irritable patients may be especially at risk.
